10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001193125-20-210627`
Period End Date	20200630
Filing Date	20200805
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	d938521d10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 87 Income Statement 88 Cash Flow Statement 52 Stockholders Equity 34 Comprehensive Income 36

Balance Sheet 87 line items

Line Item	Tag	Value	Unit	Period
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$129.00M	USD	Point-in-time
Allowance for credit losses	`AllowanceForDoubtfulAccountsReceivableCurrent`	$135.00M	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	CHF	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.40B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.98B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $129 million and $135 million as of June 30, 2020 and December 31, 2019	`AccountsReceivableNetCurrent`	$4.54B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Accounts receivables, net of allowance for credit losses of $129 million and $135 million as of June 30, 2020 and December 31, 2019	`AccountsReceivableNetCurrent`	$5.68B	USD	Point-in-time
Inventories	`InventoryNet`	$4.36B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Inventories	`InventoryNet`	$4.42B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$870.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$956.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$448.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$434.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$87.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$69.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.46B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.78B	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$386.00M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxAssetsNet`	$483.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$560.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$591.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.12B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.44B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$514.00M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$489.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$9.94B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$11.23B	USD	Point-in-time
Goodwill	`Goodwill`	$24.85B	USD	Point-in-time
Goodwill	`Goodwill`	$24.62B	USD	Point-in-time
Total assets	`Assets`	$54.99B	USD	Point-in-time
Total assets	`Assets`	$57.47B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.35B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.65B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.16B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$5.20B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.72B	USD	Point-in-time
Accounts payables	`AccountsPayableTradeCurrent`	$1.61B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$544.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$693.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.75B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.87B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$889.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$995.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$11.75B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.67B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$1.10B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAndOtherLiabilitiesNoncurrent`	$975.00M	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.41B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.64B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$24.62B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$24.56B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$414.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$435.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$28.73B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$28.42B	USD	Point-in-time
Commitments and contingencies, see note 10	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$42.41B	USD	Point-in-time
Total liabilities	`Liabilities`	$40.17B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; June 30, 2020 and December 31, 2019: authorized 2,495 million shares; issued 1,202 million shares and 1,198 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; June 30, 2020 and December 31, 2019: authorized 2,495 million shares; issued 1,202 million shares and 1,198 million shares, respectively	`CommonStockValue`	$57.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.37B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.31B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-6.75B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-6.96B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.31B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.70B	USD	Point-in-time
Treasury shares as of June 30, 2020 and December 31, 2019 107 million ordinary shares and 106 million ordinary shares, respectively	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Treasury shares as of June 30, 2020 and December 31, 2019 107 million ordinary shares and 106 million ordinary shares, respectively	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$13.85B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$13.97B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.09B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$972.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.59B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.82B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$54.99B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$57.47B	USD	Point-in-time

Income Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$8.33B	USD	2 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.87B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$8.23B	USD	2 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.18B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.40B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$2.28B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.11B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.58B	USD	2 Qtrs
Gross profit	`GrossProfit`	$1.89B	USD	1 Quarter
Gross profit	`GrossProfit`	$3.83B	USD	2 Qtrs
Gross profit	`GrossProfit`	$1.76B	USD	1 Quarter
Gross profit	`GrossProfit`	$3.75B	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$446.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$225.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$537.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$276.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$597.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$666.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.31B	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.21B	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$589.00M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$296.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$264.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$567.00M	USD	2 Qtrs
Intangible assets impairments	`IntangibleAssetsImpairments`	$561.00M	USD	1 Quarter
Intangible assets impairments	`IntangibleAssetsImpairments`	$768.00M	USD	2 Qtrs
Intangible assets impairments	`IntangibleAssetsImpairments`	$1.03B	USD	2 Qtrs
Intangible assets impairments	`IntangibleAssetsImpairments`	$120.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$502.00M	USD	2 Qtrs
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$103.00M	USD	2 Qtrs
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$101.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$381.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$703.00M	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-12.00M	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$646.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$13.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$9.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$9.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$15.00M	USD	2 Qtrs
Other income	`OtherOperatingIncomeExpenseNet`	$22.00M	USD	2 Qtrs
Operating (loss) income	`OperatingIncomeLoss`	$-510.00M	USD	2 Qtrs
Operating (loss) income	`OperatingIncomeLoss`	$173.00M	USD	1 Quarter
Operating (loss) income	`OperatingIncomeLoss`	$364.00M	USD	2 Qtrs
Operating (loss) income	`OperatingIncomeLoss`	$-644.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-206.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-425.00M	USD	2 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-448.00M	USD	2 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-223.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-51.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-84.00M	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-934.00M	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-850.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-170.00M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-163.00M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-104.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-179.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-4.00M	USD	2 Qtrs
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	-	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$53.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$78.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-131.00M	USD	2 Qtrs
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-87.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$18.00M	USD	1 Quarter
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$26.00M	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$209.00M	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-689.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$140.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-794.00M	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-0.73	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.13	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.19	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-0.63	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.73	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$0.19	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.63	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.13	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.10B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.10B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.10B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	1 Quarter

Cash Flow Statement 52 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$53.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$78.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$893.00M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$781.00M	USD	2 Qtrs
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$1.12B	USD	2 Qtrs
Impairment of long-lived assets and assets held for sale	`AssetImpairmentCharges`	$1.10B	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.00B	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.06B	USD	2 Qtrs
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-362.00M	USD	2 Qtrs
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-502.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$64.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$62.00M	USD	2 Qtrs
Net loss (gain) from sale of investments and long-lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-24.00M	USD	2 Qtrs
Net loss (gain) from sale of investments and long-lived assets	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-6.00M	USD	2 Qtrs
Other items	`OtherOperatingActivitiesCashFlowStatement`	$11.00M	USD	2 Qtrs
Other items	`OtherOperatingActivitiesCashFlowStatement`	$17.00M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$578.00M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-115.00M	USD	2 Qtrs
Beneficial interest collected in exchange for securitized accounts receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$746.00M	USD	2 Qtrs
Beneficial interest collected in exchange for securitized accounts receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$769.00M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$259.00M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$237.00M	USD	2 Qtrs
Proceeds from sale of long lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$45.00M	USD	2 Qtrs
Proceeds from sale of long lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$134.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-58.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-10.00M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$701.00M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$565.00M	USD	2 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$157.00M	USD	2 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$700.00M	USD	2 Qtrs
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	-	USD	2 Qtrs
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$52.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-15.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-3.00M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-224.00M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-703.00M	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-13.00M	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$427.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$383.00M	USD	2 Qtrs
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.40B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.17B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.40B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.98B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.17B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$770.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized accounts receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$728.00M	USD	Point-in-time

Stockholders Equity 34 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.59B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.82B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time
Net Income (loss)	`ProfitLoss`	$53.00M	USD	1 Quarter
Net Income (loss)	`ProfitLoss`	$78.00M	USD	2 Qtrs
Net Income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net Income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Other Comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$76.00M	USD	1 Quarter
Other Comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$151.00M	USD	1 Quarter
Other Comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$170.00M	USD	2 Qtrs
Other Comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-379.00M	USD	2 Qtrs
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	2 Qtrs
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	2 Qtrs
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$3.00M	USD	1 Quarter
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$6.00M	USD	2 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$32.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$62.00M	USD	2 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$64.00M	USD	2 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$32.00M	USD	1 Quarter
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$-8.00M	USD	2 Qtrs
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$-8.00M	USD	1 Quarter
Other	`OtherEquity`	$-8.00M	USD	2 Qtrs
Other	`OtherEquity`	$-2.00M	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.59B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.82B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.06B	USD	Point-in-time

Comprehensive Income 36 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$53.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$78.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$133.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-416.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$86.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$144.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-7.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$10.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-37.00M	USD	2 Qtrs
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-37.00M	USD	2 Qtrs
Unrealized gain from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	-	USD	1 Quarter
Unrealized gain from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized gain from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	2 Qtrs
Unrealized gain from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	-	USD	2 Qtrs
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	-	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	2 Qtrs
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	-	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$76.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$151.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$170.00M	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-379.00M	USD	2 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$204.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-598.00M	USD	2 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-595.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-301.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-119.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$49.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$47.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-85.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$289.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-182.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-647.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-642.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.